GovChime
AWARDDEFINITIVE CONTRACTSmall business

Definitive contract 75N93023C00001MICROBIOTIX, INC.

Overview

Award facts

Net obligations
$8.80M
$8,795,790of $14.20M potential value
Outlays (paid to date)
$2.91M
$2.91M paid of $8.80M obligated$2,905,595
Period of performance
Nov 1, 2022 to Sep 30, 2028
Ends in 22 months
Modifications
6
Latest action Nov 5, 2026
Contract type
Definitive contract
PIID 75N93023C00001

Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.

Description of requirement

TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES.

Dates and value

Award date
Signed on Oct 31, 2022
Current value
$8,795,790Base and exercised options
Potential value (if all options are exercised)
$14,195,727

Obligations by fiscal year of action

  • FY2026: $3,787,586
  • FY2025: $2,938,788
  • FY2023: $2,069,416

Total across 3 fiscal years: $8,795,790

Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Nov 5, 2026. View on USAspending · Recipient on SAM.gov

Recipient

LocationWORCESTER, MA
UEISCNKBDM341T1
CAGE code465F8
Business sizeSmall businessSize at award, per the contracting officer
Organization typeCorporate not tax exempt
Parent companyMICROBIOTIX INC.

Business types and certifications

For-profit organizationCorporation (not tax-exempt)

As represented in SAM.gov at the time of the action.

Subcontracting network

The prime, the subcontractors on this award, and their own subcontractors.

Subaward amounts are self-reported by prime contractors to SAM.gov and appear 1 to 2 months after the work. Duplicates are removed on a best-effort basis. Totals are incomplete and not an audit. Source: USAspending.

Agency and place

Awarding and funding

Awarded by
  1. Department of Health and Human Services
  2. National Institutes Of Health
  3. NATIONAL INSTITUTES OF HEALTH NIAID
Funded by
  1. Department of Health and Human Services
  2. National Institutes Of Health
  3. NATIONAL INSTITUTES OF HEALTH NIAID
Funded from
Public health and social services emergency fund; National institute of allergy and infectious diseases (0885)Program activities075-0140, 075-0885Federal accounts (agency financial reports)

Place of performance

Place of performance
Worcester, Massachusetts 01605-4307
Congressional district (place of performance)
MA-02As reported at the time of the action

Classification and competition

Classification

Competition

Extent competed
Full and open competitionA
Solicitation procedures
Negotiated proposal/quoteNP
Set-aside
No set-aside used
Contract pricing
Cost plus fixed feeU
Offers received
10

Solicitation and notices

Solicitation ID
BAA2022-1(as reported)
Solicitation date
Jan 18, 2022

Contract details

Subcontracting plan
Plan not requiredB
Cost Accounting Standards clause
Not applicable exempt from CASX
Certified cost or pricing data
Yes
Commercial procedures
Commercial products/services procedures not usedD
Government-furnished property
Transaction does not use GFE/GFPN
Bundled requirement
Not bundledH
Consolidated requirement
Not consolidatedD
Undefinitized action (terms not final)
No
Multi-year contract
No
Performance-based service acquisition
No - service where PBA is not used.N

Linked notices

Notice
Notice ID
Type
Link
Posted

Transaction history

Modification history

Base award
Oct 31, 2022Base obligation at award: $2,069,416
Latest action
Nov 5, 2026 — Other administrative actionModification P00006; administrative: no change in scope or value
Latest substantive action
Aug 21, 2026 — Option exercisedModification P00005; obligation change +$3,787,586
Actions by type
  • Base award1
  • Other administrative action4
  • Option exercised2
7 actions recorded, Oct 31, 2022 to Nov 5, 2026; each action counted once.

Similar awards

PIID
Match
Awardee

All contract data

All contract data

Every other field reported for this award, as of its latest reported action

Competition

Evaluation preference
No preference used
Local area set-aside
No
Synopsized publicly (SAM.gov / FedBizOpps)
Yes
Simplified procedures for commercial items
No

Pricing and financing

Paid by purchase card
No

Socio-economic and policy

Inherently governmental functions
Other functionsOT
Recovered materials and sustainability
No clauses included and no sustainability includedC
EPA-designated product
Not requiredE
Clinger-Cohen Act planning (IT)
No

Place and origin

Domestic or foreign entity
U.S. owned businessA
Country of product or service origin
United statesUSA
Place of manufacture
Not a manufactured end productC

Structure

Award or IDV
Award
Award type
Definitive contractD
Awarding agency code
7500
Awarding sub-tier code
7529
Contracting office code
75N930
Transactions recorded under this award key
7

Funding

Funding agency code
7500
Funding sub-tier code
7529
Funding office code
75N930
Treasury accounts
  • 075-2025/2025-0885-000
  • 075-X-0140-000
Object classes
  • 25.5: Research and development contracts
Disaster or emergency funding (DEFC)
  • Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression
  • V: Non-emergency P.L. 117-2
COVID-19 supplemental obligations
$2,069,416
COVID-19 supplemental outlays
$2,069,416